Abstract:The human γ-aminobutyric acid (GABA) transporter 1 (hGAT-1) is the first member of the solute carrier 6 (SLC6) protein superfamily. GAT-1 ( SLC6A1 ) is one of the main GABA transporters in the central nervous system. Its principal physiological role is retrieving GABA from the synapse into neurons and astrocytes, thus swiftly terminating neurotransmission. GABA is a key inhibitory neurotransmitter and shifts in GABAergic signaling can lead to pathological conditions, from anxiety and epileptic seizures to schizophrenia. Point mutations in the SLC6A1 gene frequently give rise to epilepsy, intellectual disability or autism spectrum disorders in the afflicted individuals. The mechanistic routes underlying these are still fairly unclear. Some loss-of-function variants impair the folding and intracellular trafficking of the protein (thus retaining the transporter in the endoplasmic reticulum compartment), whereas others, despite managing to reach their bona fide site of action at the cell surface, nonetheless abolish GABA transport activity (plausibly owing to structural/conformational defects). Whatever the molecular culprit(s), the physiological aftermath transpires into the absence of functional transporters, which in turn perturbs GABAergic actions. Dozens of mutations in the kin SLC6 family members are known to exhort protein misfolding. Such events typically elicit severe ailments in people, e.g., infantile parkinsonism-dystonia or X-linked intellectual disability, in the case of dopamine and creatine transporters, respectively. Flaws in protein folding can be rectified by small molecules known as pharmacological and/or chemical chaperones. The search for such apt remedies calls for a systematic investigation and categorization of the numerous disease-linked variants, by biochemical and pharmacological means in vitro (in cell lines and primary neuronal cultures) and in vivo (in animal models). We here give special emphasis to the utilization of the fruit fly Drosophila melanogaster as a versatile model in GAT-1-related studies. Jointly, these approaches can portray indispensable insights into the molecular factors underlying epilepsy, and ultimately pave the way for contriving efficacious therapeutic options for patients harboring pathogenic mutations in hGAT-1.

Molecular basis for substrate recognition and transport of human GABA transporter GAT1

Interaction of GAT1 with sodium ions: from efficient recruitment to stabilisation of substrate and conformation

The role of N-glycosylation in the stability, trafficking and GABA-uptake of GABA-transporter 1. Terminal N-glycans facilitate efficient GABA-uptake activity of the GABA transporter.

The Role of N‐glycosylation in the Stability, Trafficking and GABA‐uptake of GABA‐transporter 1

Ways of modulating GABA transporters to treat neurological disease

Transport mechanism and pharmacology of the human GlyT1

Functional and Pharmacological Aspects of GABA Transporters

A Binding Mode Hypothesis of Tiagabine Confirms Liothyronine Effect on γ-Aminobutyric Acid Transporter 1 (GAT1)

Gaba Transporter-1 Activity Modulates Hippocampal Theta Oscillation And Theta Burst Stimulation-Induced Long-Term Potentiation

The Subcellular Localization of GABA Transporters and Its Implication for Seizure Management

Cryo-EM structures of inactive and active GABA B receptor

Structural Mechanisms of Human Sodium-Coupled High-Affinity Choline Transporter CHT1

Rational Search for Betaine/GABA Transporter 1 Inhibitors─In Vitro Evaluation of Selected Hit Compound.

Molecular and Clinical Repercussions of GABA Transporter 1 Variants Gone Amiss: Links to Epilepsy and Developmental Spectrum Disorders

Cryo-EM Structures of Inactive and Gi-coupled GABAB Heterodimer

Involvement of Sialic Acid in the Regulation of -Aminobutyric Acid Uptake Activity of -Aminobutyric Acid Transporter 1

Nonvesicular Inhibitory Neurotransmission via Reversal of the GABA Transporter GAT-1

Structure of the human taurine transporter TauT reveals substrate recognition and mechanisms of inhibition

A transporter's doom or destiny: SLC6A1 in health and disease, novel molecular targets and emerging therapeutic prospects

Structure activity relationship of selective GABA uptake inhibitors

[Ethanol Affects the Function of Gamma-Aminobutyric Acid Transporter I in Mice Brain].